Advertisement
Canada markets closed

  • S&P/TSX

    21,728.55
    +14.01 (+0.06%)
     

  • S&P 500

    5,018.39
    -17.30 (-0.34%)
     

  • DOW

    37,903.29
    +87.37 (+0.23%)
     

  • CAD/USD

    0.7282
    +0.0021 (+0.29%)
     

  • CRUDE OIL

    79.13
    -2.80 (-3.42%)
     

  • Bitcoin CAD

    78,786.62
    -3,654.00 (-4.43%)
     

  • CMC Crypto 200

    1,202.07
    -136.99 (-10.23%)
     

  • GOLD FUTURES

    2,330.20
    +27.30 (+1.19%)
     

  • RUSSELL 2000

    1,980.23
    +6.32 (+0.32%)
     

  • 10-Yr Bond

    4.5950
    -0.0910 (-1.94%)
     

  • NASDAQ futures

    17,474.75
    -96.50 (-0.55%)
     

  • VOLATILITY

    15.39
    -0.26 (-1.66%)
     

  • FTSE

    8,121.24
    -22.89 (-0.28%)
     

  • NIKKEI 225

    38,274.05
    -131.61 (-0.34%)
     

  • CAD/EUR

    0.6792
    -0.0010 (-0.15%)
     
MARKETS LIVE BLOG:

STOCKS END MIXED EVEN AS POWELL SOOTHES RATE NERVES

Fed chair: "It is unlikely the next policy move will be a hike"

Osteoporosis drug helps Amgen third-quarter profit beat estimates

Deena Beasley and Carl O'Donnell
Updated ·2 min read
FILE PHOTO: An Amgen sign is seen at the company's office in South San Francisco

By Deena Beasley and Carl O'Donnell

(Reuters) - Amgen Inc <AMGN.O> on Wednesday said third-quarter adjusted profit rose 17% due to stronger sales of drugs such as osteoporosis treatment Prolia and psoriasis medication Otezla, bucking challenges from lower drug prices and COVID-19.

The company said more patients had resumed interacting with their doctors in the third quarter than earlier in the health crisis, but prescribing volumes remained "modestly below" pre-pandemic levels.

Prescriptions for drugs including rheumatology medicine Enrbel will continue to be affected by the pandemic and Amgen has factored COVID-19 into revenue guidance for the fourth quarter and the beginning of next year, it said on its quarterly call.

ADVERTISEMENT

The company raised its full-year adjusted earnings forecast to $15.80 to $16.15 per share, from a previous range of $15.10 to $15.75, and narrowed its revenue estimate. It now expects revenue of $25.1 billion to $25.5 billion versus it prior forecast of $25.0 billion to $25.6 billion.

The company reported a third-quarter adjusted profit $4.37 per share, beating the average estimate of $3.81 per share, as compiled by Refinitiv.

Revenue for the quarter rose 12% to $6.4 billion, in line with analyst estimates of $6.38 billion.

Sales of Prolia rose 11% to $701 million, ahead of the average analyst estimate of $688 million.

Psoriasis drug Otezla, acquired from Celgene Corp in November, had sales of $538 million for the quarter. Amgen said Otezla is expected to maintain its double-digit year-on-year volume growth trend, adding that as an oral pill, it is less affected by COVID-19.

Sales of Amgen's older arthritis drug Enbrel fell 3% year-on-year to $1.3 billion as the drug continued to lose market share in the quarter.

Amgen posted net income of $2.02 billion, or $3.43 per share, compared with a profit of $1.97 billion, or $3.27 a share, a year ago.

(Reporting By Deena Beasley and Carl O'Donnell; additional reporting by Shivani Singh in Bengaluru; Editing by Bill Berkrot and Sam Holmes)